~3 spots leftby Apr 2026

Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea

Recruiting in Palo Alto (17 mi)
IS
Overseen byIsabella Soreca, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: VA Office of Research and Development
No Placebo Group
Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

Sleep apnea is one of the most common chronic condition among US military Veterans, causing sleepiness, reduced psychomotor vigilance and depression, which undermine daytime functioning and quality of life. Persistent daytime symptoms of sleepiness in individuals with Obstructive Sleep Apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Residual daytime sleepiness (RDS) is associated with reduced occupational and family functioning and overall lower quality of life. Napping is a common behavior among individuals with OSA and RDS and has been linked to both benefits to and decline in health and functioning. Longer nap times may maintain, as opposed to decrease, sleepiness by promoting sleep inertia and can contribute to maintaining subclinical circadian alterations that result in higher night-tonight variability in sleep patterns. Preliminary studies in humans and animal models have shown persisting alterations of circadian rhythms in OSA patients, that fail to normalize with CPAP treatment. CPAP treatment, while effective at correcting respiratory events and night time blood oxygen saturation levels, does not necessarily re-align the circadian system. Current treatment options are limited to stimulants and modafinil, whose long-term safety profile, effectiveness and impact on functional recovery is largely unknown. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. However, no study to date has tested the application of BLT to treat daytime symptoms associated with sleep apnea. The investigators' study will be the first to explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP.

Research Team

IS

Isabella Soreca, MD

Principal Investigator

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Eligibility Criteria

Inclusion Criteria

Veterans from the VA Pittsburgh Healthcare System (VAPHS)
Documented diagnosis of OSA
Currently on CPAP or BiPAP with documented adherence (defined as wearing CPAP/BiPAP for >4h/night on at least 75% of nights)
See 2 more

Treatment Details

Interventions

  • Bright Light Therapy (Behavioural Intervention)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Retimer bright light therapy glassesExperimental Treatment1 Intervention
active bright light therapy in the green/blue spectrum range
Group II: sham-Retimer bright light therapy glassesPlacebo Group1 Intervention
bright light therapy with light in the red spectrum (not active)

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PAPittsburgh, PA
Loading ...

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1691
Patients Recruited
3,759,000+